Clinical trials
Obesity, Abdominal trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
11 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 5 |
| Unknown status | 3 |
| Enrolling by invitation | 1 |
| Not yet recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dongfang Hospital Beijing University of Chinese Medicine | 2 |
| Beijing Sport University | 1 |
| Chinese University of Hong Kong | 1 |
| Guang'anmen Hospital of China Academy of Chinese Medical Sciences | 1 |
| Hubei Hospital of Traditional Chinese Medicine | 1 |
| RenJi Hospital | 1 |
| Shanghai Mental Health Center | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| University of California, San Francisco | 1 |
| Zhejiang Provincial Tongde Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Obesity, Abdominal | 11 |
| Metabolic Syndrome | 2 |
| Obesity | 2 |
| Breast Neoplasms | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Dyslipidemias | 1 |
| Glucose Metabolism Disorders | 1 |
| Inflammation | 1 |
| Insulin Resistance | 1 |
| Lipid Metabolism Disorders | 1 |
Trials
Showing 1 to 11 of 11. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.